France’s bioMérieux has secured European CE marking for three fully automated immunoassays for dengue, the company announced Wednesday.
Performed on the company’s Vidas family platforms, the Vidas Dengue NS1 Ag, Anti-Dengue IgM and Anti-Dengue IgG are “cost-effective and suitable for low- and middle-income countries,” according to the press release.
The company plans to add a chikungunya assay to its diagnostic offerings, per the announcement.
Twelve leading pharma companies released second-quarter 2020 financial results in July, and one Japanese firm (with a fiscal year ending in March) reported first-quarter numbers.
(Figures exclude exchange rate and portfolio changes where applicable.)
Leading the pack, AstraZeneca reported an 11% hike in total revenues to reach $6.3 billion in the quarter—slightly above consensus estimates. Amid the coronavirus lockdown, the British drugmaker saw strong product sales as its…